Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate that in patients with
recuperated/normalized left ventricular function, defined as an ejection fraction (EF) ≥ 50%,
after implantation of cardiac resynchronization therapy, device treatment is sufficient and
neurohumoral blocker therapy can safely be withdrawn